Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Adenocarcinoma of Lung 1

Interventions

osimertinib 1durvalumab 1anlotinib 1aflutinib 1Radiosurgery 1Monatide (IMS 3015) 1Immunotherapy 1Docetaxel 1Circulating Tumor DNA 1Chemotherapy, Adjuvant 1Biological Assay 1Adjuvants, Pharmaceutic 1AST5902 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × AST5902 × Thoracic × Clear all
NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Peking University People's Hospital

Phase 1/2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡